 Concert Pharmaceuticals has a JAK inhibitor for alopecia areata AA that may be superior to competitive products. The company cites a figure of 1.5m US patients with AA. Published literature cites a prevalence of 700,000 patients and only 300,000 with moderate to severe AA. 